GlaxoSmithKline Pharmaceuticals Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Investors weighing a GlaxoSmithKline Pharmaceuticals target price for 2027 should start with where the stock sits today. At Rs 2,543.00 on 9 October 2026, it is 18.5% below its 52-week high of Rs 3,120.70 and 21.8% above its 52-week low of Rs 2,088.10. That range spans 49% from low to high, so the entry point matters as much as the GlaxoSmithKline Pharmaceuticals price forecast itself.

This article builds the GlaxoSmithKline Pharmaceuticals share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 3,042 base case and the Rs 3,643 bull case were reached, along with a downside risk level of Rs 2,028.

Click Here – Get Free Investment Predictions

GlaxoSmithKline Pharmaceuticals Stock Analysis: Company Overview and Key Stats

GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) has a market capitalisation of Rs 42,939 crore. In FY26 it reported revenue of Rs 3,967 crore and net profit of Rs 1,036 crore. The table collects the figures the GlaxoSmithKline Pharmaceuticals share price target is built on.

Metric	Value
Company	GlaxoSmithKline Pharmaceuticals
NSE Ticker	GLAXO
CMP (9 October 2026)	Rs 2,543.00
52-Week High	Rs 3,120.70
52-Week Low	Rs 2,088.10
Market Cap	Rs 42,939 crore
PE Ratio (TTM)	40.20
Industry PE	37.59
Price to Book	18.94
Return on Equity	45.69%
Debt to Equity	0.01
EPS (TTM)	Rs 63.05
Dividend Yield	2.25%
12-Month Base Target	Rs 3,042
Bull Case	Rs 3,643
Downside Risk Level (not a target)	Rs 2,028

Why Is GlaxoSmithKline Pharmaceuticals Share Price Target Set at Rs 3,042 for 2027?

The base-case GlaxoSmithKline Pharmaceuticals stock target of Rs 3,042 applies a PE multiple of 40.20 to a forward EPS estimate of Rs 75.66. That EPS assumes 20.0% yearly growth, the pace from FY24 to FY26, and puts the target 19.6% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the GlaxoSmithKline Pharmaceuticals Target Price: Five Years of Results

GlaxoSmithKline Pharmaceuticals grew revenue from Rs 3,354 crore in FY22 to Rs 3,967 crore in FY26, a compound annual growth rate of 4.3%. Net profit grew faster, from Rs 380.77 crore to Rs 1,036 crore (28.4% a year), which shows margin gains did part of the work and not just higher sales.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	3,353.80	380.77	100.04	90.00
FY23	3,352.38	607.64	36.05	32.00
FY24	3,576.30	589.96	34.83	32.00
FY25	3,895.14	927.58	54.76	54.00
FY26	3,967.03	1,035.98	61.15	57.00

FY26 revenue growth was 1.8%, slower than the four-year average of 4.3%, and net profit moved up 11.7%. EPS rose from Rs 34.83 in FY24 to Rs 61.15 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

GlaxoSmithKline Pharmaceuticals converted 26.1% of FY26 revenue into net profit, against 23.8% in FY25, within a five-year range of 11.4% to 26.1%. EBITDA margin was 37.2% in FY26 versus 34.1% in FY25.

In the June 2026 quarter, revenue was Rs 982.20 crore, up 15.7% from the same quarter a year earlier, while net profit of Rs 237.18 crore was up 15.7%. EBITDA came in at Rs 339.26 crore, up 15.0% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.01, and shareholders' equity grew from Rs 2,663 crore in FY22 to Rs 2,267 crore in FY26. Operating cash flow in FY26 was Rs 903.30 crore against capital expenditure of Rs 55.28 crore, leaving free cash flow of Rs 848.02 crore, or 2.0% of the current market capitalisation. In FY25 free cash flow was Rs 1,267 crore.

Valuation Check for the GlaxoSmithKline Pharmaceuticals Stock Target: PE, Price to Book and ROE

At a PE of 40.20 against an industry PE of 37.59, GlaxoSmithKline Pharmaceuticals trades in line with its industry. Price to book is 18.94 on a book value of Rs 133.85 per share, and return on equity is 45.69%. A PE of 40.20 equals an earnings yield of 2.5%, and the FY26 dividend of Rs 57.00 per share gives a yield of 2.25%.

Shareholding Pattern and Institutional Holding

Promoters held 75.00% of GlaxoSmithKline Pharmaceuticals in June 2026, and promoter holding has stayed near 75.00% since June 2025. Foreign institutional investors (FII) held 4.79% and domestic institutions (DII) held 7.80%, which puts total institutional holding at 12.59%. FII holding has stayed near 4.79% since June 2025. Public shareholders own the remaining 12.41%.

GlaxoSmithKline Pharmaceuticals Share Price Targets for the Short Term and 12 Months

Short Term GlaxoSmithKline Pharmaceuticals Stock Target Levels: Technical Setup

At Rs 2,543.00 on 9 October 2026, GlaxoSmithKline Pharmaceuticals trades below its 50-day simple moving average of Rs 2,809.05 and below its 200-day exponential moving average of Rs 2,603.22. The 14-day RSI reads 25.3, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 2,603.22 (200-day exponential moving average) and the nearest support is Rs 2,088.10 (52-week low). A sustained move above Rs 2,603.22 would improve the short-term setup, while a close below Rs 2,088.10 would shift attention to the next support.

12 Month GlaxoSmithKline Pharmaceuticals Target Price for 2027

The 12-month target for GlaxoSmithKline Pharmaceuticals is Rs 3,042: forward EPS of Rs 75.66 at a PE of 40.20. That is 19.6% above Rs 2,543.00. It would still leave the stock 2.5% below its 52-week high of Rs 3,120.70.

How EPS Growth and PE Multiple Change the GlaxoSmithKline Pharmaceuticals Target Price

EPS Growth	PE 32.16	PE 40.20	PE 46.23
0.0% (EPS Rs 63.05)	Rs 2,028	Rs 2,535	Rs 2,915
20.0% (EPS Rs 75.66)	Rs 2,433	Rs 3,042	Rs 3,498
25.0% (EPS Rs 78.81)	Rs 2,535	Rs 3,168	Rs 3,643

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the GlaxoSmithKline Pharmaceuticals price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for GlaxoSmithKline Pharmaceuticals Stock Target in 2027

Bull Case Rs 3,643

The bull case GlaxoSmithKline Pharmaceuticals price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 78.81, and a PE multiple that rises 15% to 46.23. That gives Rs 3,643, 43.3% above the current price and above the 52-week high of Rs 3,120.70, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 2,028

The downside risk level is not a target. It assumes EPS stays flat at Rs 63.05 and the PE falls 20% to 32.16. That gives Rs 2,028, 20.3% below the current price and below the 52-week low of Rs 2,088.10.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	25.0%	46.23	Rs 3,643	+43.3%
Base Case	20.0%	40.20	Rs 3,042	+19.6%
Downside Risk	0.0%	32.16	Rs 2,028	-20.3%

Key Risks to the GlaxoSmithKline Pharmaceuticals Target Price for 2027

Growth Slowdown Risk for the GlaxoSmithKline Pharmaceuticals Price Target

Revenue in the June 2026 quarter was up 15.7% year on year, and FY26 revenue growth was 1.8%. If growth slows from here, the EPS estimate behind the GlaxoSmithKline Pharmaceuticals stock target will need revising.

Liquidity and Size Risk

GlaxoSmithKline Pharmaceuticals has a market capitalisation of Rs 42,939 crore. Institutional holding is 12.59%, and promoters hold 75.00%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.

Valuation and Margin Risk

Net margin was 26.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 40.20 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 32.16 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 18.5% below its 52-week high, with an RSI of 25.3 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in GlaxoSmithKline Pharmaceuticals

Start with the live price and volume. Any GlaxoSmithKline Pharmaceuticals share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 2,543.00 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check GlaxoSmithKline Pharmaceuticals' PE, ROE, debt and shareholding in one place.

Check GlaxoSmithKline Pharmaceuticals fundamentals on the Univest Screener

Then compare the three GlaxoSmithKline Pharmaceuticals target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track GlaxoSmithKline Pharmaceuticals live price and get daily stock recommendations.

Conclusion

The GlaxoSmithKline Pharmaceuticals share price target for 2027 is Rs 3,042 in the base case, with Rs 3,643 as the bull case. The support for that view is arithmetic you can check: EPS grew 32.5% a year over FY24 to FY26, and the stock trades at a PE of 40.20. The risks are equally concrete, including a stock that sits 18.5% below its 52-week high and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on GlaxoSmithKline Pharmaceuticals Share Price Target 2027

What is the GlaxoSmithKline Pharmaceuticals share price target for 2027?

Ans. The base-case GlaxoSmithKline Pharmaceuticals share price target for 2027 is Rs 3,042, with Rs 3,643 as the bull case. The downside risk level, which is not a target, is Rs 2,028. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the GlaxoSmithKline Pharmaceuticals share price today?

Ans. As of 9 October 2026, 1:18 PM IST, GlaxoSmithKline Pharmaceuticals trades at Rs 2,543.00, up 0.34% on the day. The 52-week range is Rs 2,088.10 to Rs 3,120.70.

Is GlaxoSmithKline Pharmaceuticals a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 32.5% a year over FY24 to FY26, but the stock is 18.5% below its 52-week high. Whether GlaxoSmithKline Pharmaceuticals fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for GlaxoSmithKline Pharmaceuticals shares?

Ans. The bull case target is Rs 3,643, which assumes 25.0% EPS growth and a PE of 46.23. The downside risk level is Rs 2,028, which assumes flat EPS and a PE of 32.16. It marks a risk, not a target.

What are the main risks to the GlaxoSmithKline Pharmaceuticals price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 42,939 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of GlaxoSmithKline Pharmaceuticals and how does it compare with the industry?

Ans. The PE ratio of GlaxoSmithKline Pharmaceuticals is 40.20 against an industry PE of 37.59. Price to book is 18.94 and return on equity is 45.69%. The base case in the GlaxoSmithKline Pharmaceuticals price target holds this PE constant.

Who owns GlaxoSmithKline Pharmaceuticals, and what is the promoter holding?

Ans. Promoters held 75.00% of GlaxoSmithKline Pharmaceuticals in June 2026. FII held 4.79%, DII held 7.80% and the public held 12.41%.

What were GlaxoSmithKline Pharmaceuticals' latest quarterly results?

Ans. In the June 2026 quarter, GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore (up 15.7% year on year) and net profit of Rs 237.18 crore (up 15.7%).